Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.03
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-827612.00 · quality 66.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$874630
P/E
0.6x
↓EV/EBITDA
1.4x
↓ROE
-100.1%
↓Gross Margin
N/A
•Debt/Equity
-0.25
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
-0.42x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $745500.0 · FCF $-312799.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $217931.00 | $227268.00 | $229001.00 |
| Net Income | $745500.00 | $745500.00 | $-1.8M | $-3.0M | $-4.8M |
| EBITDA | $778384.00 | $778384.00 | $-1.7M | $-2.9M | $-4.1M |
| EPS | — | — | -0.10 | -0.25 | -0.41 |
| Gross Margin | — | — | -45.4% | -44.2% | -3.5% |
| Operating Margin | — | — | -751.1% | -1295.5% | -1810.9% |
| Net Margin | — | — | -843.0% | -1301.9% | -2117.8% |
| Balance Sheet | |||||
| Debt/Equity | -0.25 | -0.25 | -0.21 | -0.55 | — |
| Current Ratio | 0.12 | 0.12 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-312799.00 | $-312799.00 | $-827612.00 | $-1.8M | $-3.7M |
| Returns | |||||
| ROE | -100.1% | -100.1% | 85.6% | 271.6% | -293.2% |
| Valuation | |||||
| P/E | 0.63 | 0.63 | — | — | — |
| EV/EBITDA | 1.36 | 1.36 | — | — | — |
| P/B | — | — | — | — | 3.22 |
| Growth & Yield | |||||
| Revenue Growth | — | — | -4.1% | -0.8% | — |
| EPS Growth | — | — | 60.0% | 39.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-72.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.10 → n/d
Residual
-72.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.